DIBAN CAP 71.4 MG
PECTIN : 71.4 MG ATROPINE SULFATE : 9.7 MCG OPIUM : 12 MG ATTAPULGITE (ACTIVATED) : 300 MG HYOSCYAMINE SULFATE : 0.0519 MG SCOPOLAMINE HYDROBROMIDE : 3.3 MCG · DIN 02041626 · WYETH-AYERST CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is DIBAN CAP?
DIBAN CAP 71.4 MG contains PECTIN : 71.4 MG ATROPINE SULFATE : 9.7 MCG OPIUM : 12 MG ATTAPULGITE (ACTIVATED) : 300 MG HYOSCYAMINE SULFATE : 0.0519 MG SCOPOLAMINE HYDROBROMIDE : 3.3 MCG. It is listed in the Health Canada Drug Product Database under DIN 02041626, held by WYETH-AYERST CANADA INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jan-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02041626 |
|---|---|
| Brand name | DIBAN CAP |
| Generic / active ingredient | PECTIN : 71.4 MG ATROPINE SULFATE : 9.7 MCG OPIUM : 12 MG ATTAPULGITE (ACTIVATED) : 300 MG HYOSCYAMINE SULFATE : 0.0519 MG SCOPOLAMINE HYDROBROMIDE : 3.3 MCG |
| Manufacturer | WYETH-AYERST CANADA INC. |
| Strength | 71.4 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | A07DA02 OPIUM |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jan-2001 |
| Original market date | 1998-02-18 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A07DA02 OPIUM. 0 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIBAN CAP | 0.0519 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909215 |
| DONNAGEL-PG CAP | 12 MG | CAPSULE | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02041642 |
| DONNAGEL-PG LIQ | 6 G / 30 ML | LIQUID | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02041634 |
| OPIUM CAMPHRE TANIN TAB | 120 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00779520 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.